ADC Development Services Targeting TIM1

Over the past years, antibody-drug conjugates (ADCs) as a novel therapeutic agent has gained wide attention in the cancer treatment. A variety of ADCs have been designed that highlights the potential and promise of the new therapy in cancer patients. Creative Biolabs offers high-quality ADCs design, construction and analysis services to help you develop your own ADC. With experienced scientists and technicians, we have established excellent and mature systems to obtain effective ADCs targeting different targets such as the TIM1. We try our best to help you save the time and cost of the drug discovery programs by taking advantage of our expertise and innovative technology platforms.

Introduction of TIM1

T-cell immunoglobulin and mucin domain-containing protein 1 (TIM1), also known as Hepatitis A virus cellular receptor 1 (HAVcr-1), is a type I membrane protein encoded by the HAVCR1 gene. It consists of an IgV domain, a mucin domain with O-linked glycosylation, a transmembrane domain and an intracellular cytoplasmic tail with one tyrosine phosphorylation motif. TIM1 presents different functions expressing on various types of cells. Besides, its expression on human T cells plays a role in the regulation of immune responses. TIM1 is expressed by antigen-presenting cells interacting with TIM4 to mediate immune activation. In addition, TIM1 has been found involved in the regulation of B cells and dendritic cells. The molecular as a target has been investigated in some targeted therapies currently.

Fig.1 TIM family proteins and their ligands. (Kuchroo, 2008)

Anti-TIM1 ADC in RCC

TIM-1 is widely expressed in several human cancers, most notably in renal cell carcinoma (RCC). The expression and shedding of the ectodomain of TIM1 are involved in a malignant phenotype of RCC. Thus, TIM1 is considered as a useful marker in the targeted immunotherapy, such as ADCs.

CDX-014, an ADC targeting TIM1, consists of an anti-TIM1 antibody covalently linked to the potent cytotoxin, monomethyl auristatin E (MMAE). This ADC exhibited significant cytostatic or cytotoxic activity against many TIM1-positive cell lines in preclinical studies. Furthermore, clinical trials results showed that the CDX-014 has significant and powerful antitumor activity. It also presented a good safety profile in renal cell carcinoma and other TIM1-expressing tumors.

Fig.2 Mechanism of action of ADCs. (Iamele, 2015)

What Can We Do for You?

Equipped with our state-of-the-art research and manufacturing facilities, Creative Biolabs provides comprehensive ADCs design and construction services targeting the TIM1 protein. Our top-ranking services include the conventional ADC Antibody Screening, DrugLnk™ Custom Synthesis, Antibody Design and Conjugation, ADC in vitro Analysis and ADC in vivo Analysis. We are confident to offer reliable ADCs services to accelerate your drug development.

Contact us today for a free consultation with the scientific team and discover how Creative Biolabs can be a valuable resource and partner for your organization.

References

1. Kuchroo, V. K.; et al. New roles for TIM family members in immune regulation. Nature Reviews Immunology. 2008, 8(8): 577.
2. Iamele, L.; et al. Antibody-drug conjugates: Targeted weapons against cancer. Antibody Technology Journal. 2015, 5: 1.

For Research Use Only. NOT FOR CLINICAL USE.